Natalie Arnold: Biomarkers and the Hidden Burden of CHD
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in American Journal of Preventive Cardiology, adding:
“These are challenging times for preventive cardiology: two long-awaited randomized CVOTs – one targeting Lp(a), the other IL-6 mediated inflammation – did not meet their primary CV endpoints.
But neutral treatment trials do not make these biomarkers irrelevant.
They remind us that identifying risk does not automatically tell us how to modify it.
In our new study (just accepted by the American Journal of Preventive Cardiology) we measured Lp(a), hsCRP, and triglycerides in individuals classified as low risk by traditional measures.
The message is simple: the more biomarkers were elevated, the higher the observed CHD risk.
However, individuals classified as low risk but with two or three elevated biomarkers reached absolute event rates comparable to those with multiple conventional risk factors but fewer elevated biomarkers.
Why does this matter?
Low-risk individuals represent a large segment of the population and often remain outside our prevention radar, although they can collectively account for nearly one-third of incident CHD events.
The next challenge is to determine which part of this residual burden is truly modifiable, and in whom…”
Title: Incident coronary heart disease, residual risk and traditional cardiovascular risk factors in the community: The role of the lipid-inflammatory axis
Authors: Natalie Arnold, Christina Magnussen, Jessica Weimann, Alina Goßling, Fabian J. Brunner, Marco M. Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, Chiara Donfrancesco, Teresa Padró, Jonas Andersson, Pekka Jousilahti, Francisco Ojeda, Tanja Zeller, Allan Linneberg, Stefan Söderberg, Licia Iacoviello, Francesco Gianfagna, Susana Sans, Giovanni Veronesi, Barbara Thorand, Annette Peters, Hugh Tunstall-Pedoe, Frank Kee, Veikko Salomaa, Renate B. Schnabel, Kari Kuulasmaa, Stefan Blankenberg, Raphael Twerenbold, Wolfgang Koenig
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk
-
Sep 9, 2026, 15:39Alessandro Lucchesi: The Future of MPN Disease Modification
-
Sep 9, 2026, 15:10Pablo Corral: Is the Lp(a) Hypothesis Wrong?
-
Sep 9, 2026, 14:54Agnes Kisakye: Expanding Point-of-Care Ultrasound and Surgical Interventions for Hemophilia in Uganda
-
Sep 9, 2026, 14:52Jan Sloves: Addressing Diagnostic and Treatment Variability in Pelvic-Origin Varicose Veins
-
Sep 9, 2026, 14:48The French Care Pathway for Gene Therapy in Haemophilia B – CRH French Reference Center for Hemophilia Lyon
-
Sep 9, 2026, 14:43David McIntosh: The Ethics of Plasma Donation
-
Sep 9, 2026, 14:42Thirunavukkarasu Angappan: Factor VIII and IX Didn’t Get Viral-Safety Rules Until the 1980s
-
Sep 9, 2026, 14:30Alejandro González Veliz: 2026 ESC Guidelines Expand Cardiac Rehabilitation Beyond Post-Event Recovery